• Cantor Fitzgerald maintains their "Overweight" rating on Prenetics Global (PRE, Financial).
• Price target raised from $26.00 to $32.00, marking a 23.08% increase.

On October 29, 2025, Cantor Fitzgerald, renowned for its market analyses, announced an update on Prenetics Global (PRE). Analyst Ross Osborn has maintained an "Overweight" rating on the company, underscoring a strong confidence in its market performance.

The advisory firm has also revised its price target for Prenetics Global (PRE, Financial), elevating it from a previous $26.00 to a new target of $32.00. This adjustment reflects a substantial 23.08% increase, signaling positive expectations for the future trajectory of the stock.

Investors may view this price target hike as a significant indicator of Prenetics Global's (PRE, Financial) potential upward momentum in the stock market. With Cantor Fitzgerald's continued positive outlook, market participants could perceive this as an opportunity for potential growth in their portfolios.

Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.

Wall Street Analysts Forecast

Based on the one-year price targets offered by 1 analysts, the average target price for Prenetics Global Ltd (PRE, Financial) is $26.00 with a high estimate of $26.00 and a low estimate of $26.00. The average target implies an upside of 106.35% from the current price of $12.60. More detailed estimate data can be found on the Prenetics Global Ltd (PRE) Forecast page.

Based on the consensus recommendation from 1 brokerage firms, Prenetics Global Ltd's (PRE, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Based on GuruFocus estimates, the estimated GF Value for Prenetics Global Ltd (PRE, Financial) in one year is $9.85, suggesting a downside of 21.83% from the current price of $12.6. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Prenetics Global Ltd (PRE) Summary page.



This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to editors@gurufocus.com.